[Suppression of FcRII by intravenously administerd IgG is dependent of preparation procedures of immunoglobulins].
The effect of different i.v. IgG preparations on FcRII-dependent platelet activation by antibodies from patients with heparin-associated thrombocytopenia (HAT) was investigated. Only one preparation (treated with pH 4 and traces of pepsin) sufficiently inhibited FcRII-dependent platelet activation (20 mg/ml). We conclude that administration of high-dose i.v. IgG is efficient for acute treatment of HAT, dependent on the manufacturing process.
Greinacher
A
A
Institut für Klinische Immunologie und Transfusionsmedizin, Justus-Liebig-Universität Giessen, Deutschland.
Möckel
M
M
Mueller-Eckhardt
C
C
D006493:Heparin; D006801:Humans; D007074:Immunoglobulin G / Q000145:classification / Q000276:immunology*; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000627:therapeutic use*; D015539:Platelet Activation; D017452:Receptors, IgG / Q000502:physiology*; D013921:Thrombocytopenia / Q000097:blood / Q000276:immunology* / Q000628:therapy*
D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D017452:Receptors, IgG; D006493:Heparin
Die Hemmung des FcRII durch intravenös applizierbares IgG ist abhängig vom Herstellungsverfahren der Immunglobuline.